Navigation Links
Clues Found to How Different Flu Vaccines Work
Date:3/31/2010

Japanese study reveals that immune response is unique to each type of shot

WEDNESDAY, March 31 (HealthDay News) -- A new Japanese study outlines the molecular and cellular reasons why some flu vaccines work better than others and could point the way to better protection with fewer side effects.

"By understanding the molecular mechanism of different flu vaccines through our findings, not only the rationale for current live-attenuated influenza vaccine for children, currently available in the United States, is warranted, but also what kind of adjuvant is needed for safer as well as efficient flu vaccine development," said Dr. Ken J. Ishii, an adjunct professor in the Osaka University Laboratory of Vaccine Science in Suita. He is lead author of a report in the March 31 issue of Science Translational Medicine.

An adjuvant is something added to a vaccine to increase the immune system's response. Adjuvants are not used in U.S. flu vaccines, although they are added to such vaccines in some other countries.

The journal report describes how Ishii and his colleagues methodically injected mice with the different kinds of flu vaccines that can be used: live virus, which contains a weakened form of the flu virus; inactivated whole-virus, in which the virus has been killed by heat or chemical treatment; and split-virus, which contain a fragment of the virus. The researchers then studied in detail the immune system response to each vaccine.

Split-virus flu vaccines are used in the United States. The study found that whole-virus vaccines provoke a greater immune response, which has both a good and a bad side, said David Topham, a flu virus expert who is an associate professor of microbiology and immunology at the University of Rochester in New York.

"The whole-virus vaccine is reactogenic," meaning that it can cause pain at the site of injection and other side effects, Topham said. The slightly lower immune response produced by a split-virus vaccine is offset by a reduction in side effects, he explained.

The most significant finding of the Japanese study was identification of a rare immune system cell type, dendritic, or plasmacytoid, plasma cells, which control the effect of inactivated flu virus vaccines, Ishii said. The study showed that those cells play no role in the response to split-virus vaccines, "thereby enabling us to understand why and how different flu vaccines work or sometimes do not work well," he said.

"We know that these dendritic cells are extremely sensitive to viral RNA," Topham said. "They have different ways of recognizing viruses."

RNA is the genetic material of influenza viruses.

While the Japanese work "doesn't contain a whole lot of things we didn't know before," Topham said, it does present a valuable map of the flu vaccine territory.

"Our findings certainly help clinicians understand why one shot of the swine flu vaccine worked well and why seasonal vaccines do not work well in children," Ishii said.

More information

Flu viruses and vaccines against them are described by the U.S. Centers for Disease Control and Prevention.



SOURCES: Ken J. Ishii, M.D., Ph.D., adjunct professor, Osaka University Laboratory of Vaccine Science, Suita, Japan; David Topham, Ph.D., associate professor, microbiology and immunology, University of Rochester, Rochester, N.Y.; March 31, 2010, Science Translational Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Clues to pregnancy-associated breast cancer found
2. Blood Gives Clues to Executive Thinking Problems
3. New Clues to Lupus Link With Heart Disease
4. New clues found linking larger animals to colder climates
5. Chickens May Provide Clues to Color Vision
6. Tiny fruit fly could offer big clues in fight against obesity, researcher says
7. Review Spotlights Clues to Serious Childhood Infection
8. Genes, Diet Offer New Clues to Parkinsons Disease
9. Team finds childhood clues to adult schizophrenia
10. Compulsive Dogs Yield Clues to Human OCD, Autism
11. Clues to Cancer That Could Wipe Out Tasmanian Devils
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect Plugin ... whole new perspective by using the title layers in ProSlice Levels to split-up ... Levels contains over 30 Different presets to choose from. FCPX users can ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology: